Uric Acid Lowering Trial in Youth Onset T2D (ULTRA-T2D)

University of Colorado Denver (CU Denver)

Status and phase: Enrolling; Phase 2

Conditions: Diabetic Nephropathies; Diabetes Complications; Diabetes; Type2 Diabetes; Hyperuricemia; Type 2 Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Kidney Disease

Treatments: Drug: Pegloticase 8 MG/ML [Krystexxa]

Study type: Interventional

Funder types: Other

Identifiers

NCT03899883

18-1700

Details and patient eligibility

About

Adolescents and young adults with youth-onset type 2 diabetes (T2D) are disproportionally impacted by hyperuricemia compared to non-diabetic peers and youth with type 1 diabetes (T1D). In fact, 50% of males with youth-onset T2D have serum uric acid (SUA) greater than 6.8 mg/dl. The investigators also recently demonstrated that higher SUA conferred greater odds of developing hypertension and diabetic kidney disease (DKD) in youth with T2D over 7 years follow-up. Elevated SUA is thought to lead to cardiovascular disease (CVD) and DKD by inflammation, mitochondrial dysfunction and deleterious effects on nephron mass. While there are studies demonstrating beneficial effects of uric acid (UA) lowering on vascular health in the general population, there are no studies in youth-onset T2D. Youth-onset T2D carries a greater risk of DKD and CVD compared to adult-onset T2D and T1D.

Accordingly, a clinical trial evaluating UA lowering therapies is needed in youth-onset T2D. Krystexxa (pegloticase), a uricase, effectively lowers SUA and therefore holds promise as a novel therapy to impede the development of CVD and DKD in youth-onset T2D. This proposal describes a pilot and feasibility trial evaluating the effect of UA lowering by pegloticase on markers of CVD and DKD in ten (n=10) youth aged 18-25 with youth-onset T2D (diagnosed <21 years of age) over 7 days. The overarching hypothesis is that pegloticase improves marker of cardiorenal health by lowering UA.

Enrollment: 10 estimated patients

Sex: Male

Ages: 18 to 25 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Men
• Ages 18-25
• Youth-onset T2D (diagnosis <21 years)
• serum uric acid ≥ 5 mg/dl

Exclusion criteria

• Glucose-6-phosphate (G6P) deficiency
• Allergies to seafood or iodine
• MRI contraindications (severe claustrophobia, non-MRI compatible implantable devices, weight ≥ 450 lbs)
• HbA1C ≥ 12%
• Recent (1 month prior) diagnosis of diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemia
• Congestive heart failure
• History of multiple and/or severe allergies or anaphylactic reactions
• Uric acid lowering medications (ie: allopurinol, febuxostat)
• Pegvisomant, pegvaliase, peginterferon alfa 2b, peginterferon alfa 2a, pegfilgrastim, pegaspargase, pegaptanib, pegademase and certolizumab pegol
• Participation in another investigational study within 2 weeks prior to study

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

10 participants in 1 patient group

Pegloticase

Experimental group

Description:

Single administration of pegloticase (8 mg IV in 250 mL 0.9% normal saline)

Treatment:

Drug: Pegloticase 8 MG/ML [Krystexxa]